Physician profile
Blake C Rodgers
NPI 1366501140
$1,898.05
in general payments reported to CMS, 2019-2025
19 companies · $17.16 in 2025
The $17.16 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $810 · 2020: $289 · 2021: $316 · 2022: $87.24 · 2023: $209 · 2024: $170 · 2025: $17.16.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $396.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $395.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alphatec Spine, INC | $655.36 | 2019 | |
| Abbvie INC. | $307.90 | 2020-2025 | Qulipta, Vraylar |
| Lilly USA, LLC | $165.10 | 2020-2024 | Mounjaro, Zepbound |
| Braintree Laboratories, INC. | $144.99 | 2021 | |
| Allergan, INC. | $122.27 | 2019-2021 | |
| Novo Nordisk INC | $104.57 | 2019-2024 | Ozempic, Rybelsus |
| Amgen INC. | $87.17 | 2020-2024 | Otezla, Repatha |
| Janssen Pharmaceuticals, INC | $51.58 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $40.13 | 2019-2023 | Farxiga |
| Amarin Pharma, INC. | $37.13 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $34.44 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $22.57 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.32 | 2021 | |
| Dexcom, INC. | $22.03 | 2022 | |
| Astellas Pharma US INC | $17.90 | 2024 | Veozah |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermira, INC. | $17.61 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.54 | 2023 | |
| Pfizer INC. | $14.16 | 2021 | |
| Merck Sharp & Dohme LLC | $13.28 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Blake Rodgers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.